Publications

Richmond Pharmacology is committed to publishing data from clinical trials, however, we will only do so in agreement with our clients or where we own the intellectual property. You can read a selection of publications grouped by the area of research.

Open Dropdown

Cardiac Safety

Sex Hormones and the QT Interval

Sex Hormones and the QT Interval

Sex Hormones and the QT Interval: J‐Tpeak and Tpeak‐Tend Assessment and Further Insights Into the Physiological Effects.

View publication
Sex differences in subinterval measurements

Sex differences in subinterval measurements

Sex differences in subinterval measurements in intervention-free, fasted ECGs from seven intensive QT studies.

View publication
The differences between two algorithms

The differences between two algorithms

The differences between two algorithms used to measure ECG subintervals in intervention-free, fasted volunteers taking part in an intensive QT study.

View publication
Do hERG blocking agents further increase

Do hERG blocking agents further increase

Do hERG blocking agents further increase the risk of sudden cardiac death in patients with type 1 diabetes?

View publication
Concentration-QTC Analysis of a Cholinomimetic Agent

Concentration-QTC Analysis of a Cholinomimetic Agent

Concentration-QTC Analysis of a Cholinomimetic Agent Integrated into a Phase 1 – Japanese Bridging Study Using Intensive ECG Assessments

View publication
Influence of calcium blockade on the QT effects of a meal

Influence of calcium blockade on the QT effects of a meal

Influence of calcium blockade on the QT effects of a meal – Food ingestion in healthy volunteers leads to an increase in heart rate cardiac stroke volume.

View publication
Confirmation of the Cardiac Safety of PGF2α Receptor Antagonist

Confirmation of the Cardiac Safety of PGF2α Receptor Antagonist

Confirmation of the Cardiac Safety of PGF2α Receptor Antagonist in a First-In-Human Study in Healthy Subjects, Using Intensive ECG Assessments.

View publication
Diurnal Profile of the QTc Interval

Diurnal Profile of the QTc Interval

Diurnal Profile of the QTc Interval Following Moxifloxacin Administration | J. Täubel , G. Ferber, S. Fernandes, A. John Camm.

View publication
The cardiovascular effects of a meal

The cardiovascular effects of a meal

The cardiovascular effects of a meal: assessment of the effects on J-Tpeak and Tpeak-Tend intervals

View publication
 A Phase I study to investigate the effects of Clascoterone on QT interval

A Phase I study to investigate the effects of Clascoterone on QT interval

A Phase I study to investigate the effects of Clascoterone on QT interval using the effects of a meal on QTc to demonstrate ECG assay sensitivity

View publication
Confirmation of the Cardiac Safety of P218

Confirmation of the Cardiac Safety of P218

Confirmation of the Cardiac Safety of P218, a new Investigational Medicinal Product for Prevention of Malaria using Intensive ECG Assessments and the Effect of a Meal on QTC to show Assay Sensitivity.

View publication
Assessment of C-Peptide Effects on Cardiac Ion Channel Currents

Assessment of C-Peptide Effects on Cardiac Ion Channel Currents

Assessment of C-Peptide Effects on Cardiac Ion Channel Currents. J. Täubel, G. Ferber, Teresa del Bianco, S. Fernandes, Dilshat Djumanov, A. John Camm.

View publication
Comparison of ECG Parameters Using GE Getemed Continuous ECG Holter and MAC-1200 Bedside ECG

Comparison of ECG Parameters Using GE Getemed Continuous ECG Holter and MAC-1200 Bedside ECG

Comparison of ECG Parameters Using GE Getemed Continuous ECG Holter and MAC-1200 Bedside ECG. Jörg Täubel, Teresa Del Bianco, Sara Fernandes, Boaz Mendzelevski, Dilshat Djumanov, George Ferber.

View publication
Cardiac Safety of Rupatadine in a Single-Ascending-Dose and Multiple-Ascending-Dose

Cardiac Safety of Rupatadine in a Single-Ascending-Dose and Multiple-Ascending-Dose

Cardiac Safety of Rupatadine in a Single-Ascending-Dose and Multiple-Ascending-Dose Study in Healthy Japanese Subjects, Using Intensive Electrocardiogram Assessments – Comparison With the Previous White Caucasian Thorough QT Study

View publication
 Estimation of the Power of the Food Effect on QTc

Estimation of the Power of the Food Effect on QTc

Estimation of the Power of the Food Effect on QTc to Show Assay Sensitivity. Georg Ferber, PhD, Sara Fernandes, PhD, and Jörg Täubel,MD, FFPM.

View publication
Confirmation of the Cardiac Safety of OBE022

Confirmation of the Cardiac Safety of OBE022

Confirmation of the Cardiac Safety of OBE022 in a First in Human Study in Healthy Subjects using Intensive ECG Assessments and the Effect of a Meal on QTc to Show Assay Sensitivity – One of the objectives of this first-in-human study was

View publication
The 24 Hour Profile of Moxifloxacin Effect on QTc

The 24 Hour Profile of Moxifloxacin Effect on QTc

The 24 Hour Profile of Moxifloxacin Effect on QTc – A Reflection of Diurnal Variations – This study aims to define the time course of the effect of moxifloxacin on the QT-interval with continuous Holter data in order to better understand

View publication
QT prolongation in healthy Japanese subjects

QT prolongation in healthy Japanese subjects

QT prolongation in healthy Japanese subjects receiving moxifloxacin in Thorough QT studies. Taubel et al. The 32nd Annual Meeting of The Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT), 1-3 December 2011, Tokyo, Japan. Program

View publication
Sex differences on the effect of moxifloxacin

Sex differences on the effect of moxifloxacin

Sex differences on the effect of moxifloxacin – A meta-analysis of five Thorough QT Studies. Taubel et al. The 32nd Annual Meeting of The Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT), 1-3 December 2011, Tokyo, Japan.

View publication
Alternative methods for the confirmation of assay sensitivity in Thorough QT studies

Alternative methods for the confirmation of assay sensitivity in Thorough QT studies

Alternative methods for the confirmation of assay sensitivity in Thorough QT studies. Taubel et al. The 32nd Annual Meeting of The Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT), 1-3 December 2011, Tokyo, Japan. Program

View publication
Retrospective analysis of ECG data

Retrospective analysis of ECG data

Retrospective analysis of ECG data derived from a four-way cross over study involving a broad spectrum anti-infective agent nitazoxanide. Taubel et al. Pharmacology 2013, London, UK, 17-19 December 2013

View publication
Moxifloxacin effect on QTc interval

Moxifloxacin effect on QTc interval

Moxifloxacin effect on QTc interval in the fed and fasted states in Thorough QT studies. Jorg Taubel MD FFPM. DIA/FDA Cardiovascular Safety in Drug Development: State-of-the-art Assessments, Washington 18th April 2012

View publication
The Impact of Insulin Levels on QTc Interval in Thorough QT Studies

The Impact of Insulin Levels on QTc Interval in Thorough QT Studies

The Impact of Insulin Levels on QTc Interval in Thorough QT Studies Conducted in Healthy Subjects. Taubel et al. ACCP Annual Meeting, San Diego 23-25 September 2012

View publication
Retrospective Validation using PK-PD modelling of ECG data

Retrospective Validation using PK-PD modelling of ECG data

Retrospective Validation using PK-PD modelling of ECG data derived from a Single Ascending Dose study in accordance with the principles of the ICH E14 guideline utilising the effects of a Meal to establish assay sensitivity. 2013 Annual Meeting

View publication
Comparison of digital 12-lead ECG and digital 12-lead holter ECG

Comparison of digital 12-lead ECG and digital 12-lead holter ECG

Comparison of digital 12-lead ECG and digital 12-lead holter ECG recordings in health male subjects. 112th ASCPT Annual Meeting, March 2-5, 2011, Dallas, TX. Poster Number: PI-08, scheduled on 3/3/2011 from 8:00 AM.

View publication
Late Changes After a Euglycaemic Insulin Clamp

Late Changes After a Euglycaemic Insulin Clamp

Late Changes After a Euglycaemic Insulin Clamp Can Lead to Significant Increases in QTcF In Healthy Subjects. Taubel et al. 2012 ACCP Annual Meeting, San Diego 23-25 September 2012

View publication
Confirmation of the Cardiac Safety of Rupatadine in a Single Ascending Dose and Multiple Ascending Dose

Confirmation of the Cardiac Safety of Rupatadine in a Single Ascending Dose and Multiple Ascending Dose

Confirmation of the Cardiac Safety of Rupatadine in a Single Ascending Dose and Multiple Ascending Dose Study in Japanese Healthy Subjects Using Intensive ECG Assessments. Jorg Taubel · Georg Ferber · Inaki Izuierdo. 2015 Annual Meeting, San

View publication
Investigating the effect of intravenous APD421 (Amilsulpride) and the ethnic differences

Investigating the effect of intravenous APD421 (Amilsulpride) and the ethnic differences

Investigating the effect of intravenous APD421 (Amilsulpride) and the ethnic differences between Japanese and Caucasians on cardiac conduction. Jorg Taubel · Georg Ferber · Gabriel Fox · Sara Fernandes · Ulrike Lorch · A John Camm. Tokyo, The

View publication
The Power Of Phase I Studies To Detect Clinically Relevant Qtc Prolongation

The Power Of Phase I Studies To Detect Clinically Relevant Qtc Prolongation

The Power Of Phase I Studies To Detect Clinically Relevant Qtc Prolongation – Results From A Resampling Simulation Study. Ferber et al. The 35th Annual Meeting of The Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT), 4-6

View publication
Repeated supratherapeutic dosing of strontium ranelate

Repeated supratherapeutic dosing of strontium ranelate

Repeated supratherapeutic dosing of strontium ranelate over 15 days does not prolong QTc interval in healthy volunteers. Taubel et al. Br J Clin Pharmacol 2012;74(2): 296-303

View publication
Insulin at normal physiological levels does not prolong QTc interval

Insulin at normal physiological levels does not prolong QTc interval

Insulin at normal physiological levels does not prolong QTc interval in thorough QT studies performed in healthy volunteers. Taubel et al. Br J Clin Pharmacol 2012;75(2): 392-403

View publication
Lamotrigine does not prolong QTc in TQT studies

Lamotrigine does not prolong QTc in TQT studies

Lamotrigine does not prolong QTc in TQT studies in healthy subjects. Dixon R et al. Br J Clin Pharmacol 2008;66(3):396-404

View publication
Thorough QT study of the effect of oral moxifloxacin on QTc interval

Thorough QT study of the effect of oral moxifloxacin on QTc interval

Thorough QT study of the effect of oral moxifloxacin on QTc interval in the fed and fasted state in healthy Japanese and Caucasian subjects. Taubel J et al. Br J Clin Pharmacol 2014;77 (1), 170-179

View publication
Mason-Likar electrode configuration

Mason-Likar electrode configuration

Mason-Likar electrode configuration can confound the recognition of electrode cable interchange. Velislav N et al. J Electrocard, 2010.12.164

View publication
Investigating the Ethnic Differences between the Effect of Moxifloxacin on Cardiac Conduction

Investigating the Ethnic Differences between the Effect of Moxifloxacin on Cardiac Conduction

Investigating the Ethnic Differences between the Effect of Moxifloxacin on Cardiac Conduction in Japanese and Caucasians. Dr Jorg Taubel MD FFPM. 5th DIA Cardiac Safety Workshop in Japan, 24 October 2014, Tokyo, Japan

View publication
Comparison of Six Commonly Used QT Correction Models and Their Parameter Estimation Methods

Comparison of Six Commonly Used QT Correction Models and Their Parameter Estimation Methods

Comparison of Six Commonly Used QT Correction Models and Their Parameter Estimation Methods. Wang et al. Journal of Biopharmaceutical Statistics 2012; 22(6):1148-1161

View publication
Shortening of the QT Interval After Food

Shortening of the QT Interval After Food

Shortening of the QT Interval After Food Can Be Used to Demonstrate Assay Sensitivity in Thorough QT Studies. Taubel et al. J Clin Pharmacol, 2012;52:1558-1565

View publication
Levofloxacin can be used as a positive control in QT/QTc

Levofloxacin can be used as a positive control in QT/QTc

Levofloxacin can be used as a positive control in QT/QTc studies in healthy subjects (paper). Taubel J et al. Br J Clin Pharmacol 2010;69(4):391-400

View publication
Bupivacaine Extended Release Liposome Injection

Bupivacaine Extended Release Liposome Injection

Bupivacaine Extended Release Liposome Injection Does Not Prolong QTc Interval in a Thorough QT/QTc Study in Healthy Volunteers. Naseem et al. J Clin Pharmacol, 2012;52:1441-1447

View publication
Comparison of the effects of levofloxacin on QT/QTc interval

Comparison of the effects of levofloxacin on QT/QTc interval

Comparison of the effects of levofloxacin on QT/QTc interval assessed in both healthy Japanese and Caucasian subjects. Sugiyama et al. Br J Clin Pharmacol 2011;73(3): 455-459

View publication
Analyzing the Relationship of QT Interval and Exposure to Nitazoxanide

Analyzing the Relationship of QT Interval and Exposure to Nitazoxanide

Analyzing the Relationship of QT Interval and Exposure to Nitazoxanide, a Prospective Candidate for Influenza Antiviral Therapy – A Formal TQT Study. Taubel et al. J Clin Pharmacol, 2014. Submitted for publication 24 February 2014;

View publication
Concentration-Effect Modeling Based on Change From Baseline

Concentration-Effect Modeling Based on Change From Baseline

Concentration-Effect Modeling Based on Change From Baseline to Assess the Prolonging Effect of Drugs on QTc Together With an Estimate of the Circadian Time Course. Ferber et al. J Clin Pharmacol, 2014. Submitted for publication 3 April 2014;

View publication
Single Doses up to 800 mg of E-52862

Single Doses up to 800 mg of E-52862

Single Doses up to 800 mg of E-52862 Do Not Prolong the QTc Interval – A Retrospective Validation by Pharmacokinetic- Pharmacodynamic Modelling of Electrocardiography Data Utilising the Effects of a Meal on QTc to Demonstrate ECG Assay

View publication
Assay Sensitivity in QT Assessment

Assay Sensitivity in QT Assessment

Assay Sensitivity in QT Assessment. Taubel J et al. Journal for Clinical Studies 2015, 7(6): 60-62

View publication
Do hERG blocking agents further increase the risk of sudden cardiac death in patients with type 1 diabetes?

Do hERG blocking agents further increase the risk of sudden cardiac death in patients with type 1 diabetes?

The data from this study suggest that QT prolonging drugs should be administered with caution to type 1 diabetic patients.

View publication
Effects of progesterone and estradiol on QT subintervals over the course of a menstrual cycle

Effects of progesterone and estradiol on QT subintervals over the course of a menstrual cycle

This study aimed to assess whether there is a reliable evidence for the influence of a menstrual cycle on the duration of cardiac subintervals.

View publication

Clinical Pharmacology and Adaptive Early Phase Studies

Practical Risk Management

Practical Risk Management for Adaptive Integrated Early Phase Clinical Trials Method.

View publication

Pharmacokinetics and Safety of the Oral Prostaglandin F2 alpha Receptor Antagonist OBE022

Pharmacokinetics and Safety of the Oral Prostaglandin F2 alpha Receptor Antagonist OBE022: A First-In-Human Study in Healthy Post-Menopausal Women.

View publication

The Pharmacokinetic Interaction of the Selective PGF2α Receptor Antagonist OBE022

The Pharmacokinetic Interaction of the Selective PGF2α Receptor Antagonist OBE022 on Co-Administration with MgSO4, Atosiban, Nifedipine or Betamethasone

View publication

Efficient Design of Integrated and Adaptively Interlinked

Efficient Design of Integrated and Adaptively Interlinked Early Phase Drug Development Programmes.

View publication

Clinical Trials

Clinical Trials: A Practical Guide to Design, Analysis, and Reporting Crossover Trials Bioequivalence Trials Source and Control of Bias

View publication

The pharmacokinetic interaction between isoniazid/pyrazinamide and TMC207

The pharmacokinetic interaction between isoniazid/pyrazinamide and TMC207, an investigational antimycobacterial agent.

View publication

PET500 A Newly Formulated Tetracaine Product

PET500 A Newly Formulated Tetracaine Product is Effective in Reducing Penile Sensitivity. Taube et al. Thirty-Ninth Annual Meeting American College of Clinical Pharmacology September 12-14, 2010 Baltimore, Maryland. J Clin Pharmacol, September

View publication

Analysis of safety, pharmacokinetic and pharmacodynamic data

Analysis of safety, pharmacokinetic and pharmacodynamic data derived from a single ascending dose Phase 1 study involving a promising non-cytotoxic anti-cancer agent Sulforadex®. Taubel et al. Pharmacology 2013, London, UK, 17-19 December 2013

View publication

No clinically relevant effect of TMC125 on the pharmacokinetics

No clinically relevant effect of TMC125 on the pharmacokinetics of oral contraceptives. Schöller-Gyüre M et al.

View publication

A phase I, randomised single center, open-label parallel group trial to compare the pharmacokinetics

A phase I, randomised single center, open-label parallel group trial to compare the pharmacokinetics of NOMAC between healthy female adolescents (aged 14-17 years) and healthy female adults (aged 18-50 years) after single dose administration of

View publication

The influence of a low fat diet and hospitalisation on liver function tests

The influence of a low fat diet and hospitalisation on liver function tests in healthy Japanese and Caucasian male volunteers resident in a Phase I unit for up to 34 days. 2013 Annual Meeting of the American College of Clinical Pharmacology

View publication

How adaptive study design

How adaptive study design can enrich an early phase multiple ascending dose study. Lorch et al. 2014 Annual Meeting of the American College of Clinical Pharmacology (ACCP),Atlanta, GA , 14-16 September 2014

View publication

Ascending single-dose study with ACT-280778, a non-dihydropyridine, dual L- and T-type calcium channel blocker

Ascending single-dose study with ACT-280778, a non-dihydropyridine, dual L- and T-type calcium channel blocker: safety, tolerability, pharmacokinetics, and effect of food in healthy male subjects. Mueller MS et al. Presented at the American

View publication

Effects on 24-Hour Intragastric pH

Effects on 24-Hour Intragastric pH: A Comparison of Lansoprazole Administered Nasogastrically in Apple Juice and Pantoprazole Administered Intravenously. Freston J et al. The American Journal of Gastroenterology Vol. 96, No. 7, 2001

View publication

Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab)

Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-inhuman study Zhenhua Xu et al. Br J Clin Pharmacol 2011 72(2) / 270-281

View publication

Cizolirtine Citrate (E-4018) in the Treatment of Chronic Neuropathic Pain

Cizolirtine Citrate (E-4018) in the Treatment of Chronic Neuropathic Pain. Shembalkar P et al. Curr Med Res Opin 17(4):262-266, 2001

View publication

Rule Britannia – the advantages of conducting first-time-in-human (FTIH) studies in the UK

Rule Britannia – the advantages of conducting first-time-in-human (FTIH) studies in the UK compared to other European markets. Taubel J, Berelowitz K, Lorch U. International Clinical Trials P16+ February 2011

View publication

The practical application of adaptive study design in early phase clinical trials

The practical application of adaptive study design in early phase clinical trials: a retrospective analysis of time savings. Lorch et al. Eur J Clin Pharmacol (2012) 68:543-551

View publication

Transient paradoxical bronchospasm associated with inhalation of the LAMA AZD9164

Transient paradoxical bronchospasm associated with inhalation of the LAMA AZD9164: analysis of two Phase I, randomised, double-blind, placebo-controlled studies. Jorup et al. BMC Pulmonary Medicine 2014, 14:52

View publication

Early phase clinical trials in the United Kingdom

Early phase clinical trials in the United Kingdom. Jorg Taubel, Richmond Pharmacology Ltd and David Rogers, Medicines Evaluation Unit Ltd, Wythenshawe Hospital.

View publication

Three steps to writing adaptive study protocols

Three steps to writing adaptive study protocols in the early phase clinical development of new medicines. Lorch et al. BMC Medical Research Methodology 2014, 14:84 http://www.biomedcentral.com/1471-2288/14/84

View publication

Japanese Studies

The safety, tolerability and pharmacokinetics of AZD5069, a novel CXCR2 antagonist

The safety, tolerability and pharmacokinetics of AZD5069, a novel CXCR2 antagonist,in healthy Japanese volunteers. Lorch et al. ERS 2012, September 1-5, Vienna, Austria

View publication

Similar Rivastigmine Pharmacokinetics and Pharmacodynamics

Similar Rivastigmine Pharmacokinetics and Pharmacodynamics in Japanese and White Healthy Participants Following the Application of Novel Rivastigmine Patch. Lefèvre et al. J Clin Pharmacol April 2009 49: 430-443

View publication

Gastric Acid Suppression Effect of TAK-438, A Potassium-Competitive Acid Blocker

Gastric Acid Suppression Effect of TAK-438, A Potassium-Competitive Acid Blocker Following Ascending Single Doses in Healthy Subjects. Sakurai et al. 20th United European Gastroenterology Week, Amsterdam, The Netherlands, 20-24 Oct 2012. GUT

View publication

Pharmacokinetics and tolerability of sublingual fentanyl

Pharmacokinetics and tolerability of sublingual fentanyl in healthy Japanese and Caucasian volunteers: Phase I, open-label, single-dose study. Lorch U et al.

View publication

Gastric Acid Suppression Effect of TAK-438, A Potassium-Competitive Acid Blocker

Gastric Acid Suppression Effect of TAK-438, A Potassium-Competitive Acid Blocker Following Ascending Multiple Doses in Healthy Subjects. Jenkins et al. 20th United European Gastroenterology Week, Amsterdam, The Netherlands, 20-24 Oct 2012. GUT

View publication

Pharmacokinetics, Safety and Tolerability of Rupatadine

Pharmacokinetics, Safety and Tolerability of Rupatadine in Healthy Japanese Volunteers. Jorg Taubel · Eva Santamaria. 2015 Annual Meeting of the American College of Clinical Pharmacology, San Francisco, CA; 09/2015

View publication

Early Phase Japanese Bridging Studies

Early Phase Japanese Bridging Studies; Their Global Significance and What to Look for when Selecting a Suitable Contract Research Organisation to Conduct these Studies. Berelowitz K et al. International Pharmaceutical Industry; Volume 3, Issue

View publication

Lomitapide single-and multiple-dose exposure

Lomitapide single-and multiple-dose exposure in Japanese and Caucasian subjects: results of a Phase 1 pharmacokinetic and pharmacodynamic study. Taubel et al. The 46th Annual Scientific Meeting of the Japan Atherosclerosis Society, Tokyo, Japan,

View publication

Patient Studies

Diurnal and Racial Variance of White Blood Cell Parameters

Diurnal and Racial Variance of White Blood Cell Parameters in Early Phase Clinical Trials: A Retrospective Analysis of Pooled Data from Multiple Phase I Trials

View publication

Occult Hepatic Steatosis

Occult Hepatic Steatosis – How can we distinguish true treatment emerging liver signals from undetected, unrelated liver abnormalities?

View publication

Concentration-Effect Modelling of Blood-Pressure

Concentration-Effect Modelling of Blood-Pressure in Early Stage Trials

View publication

Efficacy and Safety of MED2005, a Topical Glyceryl Trinitrate Formulation, in the Treatment of Erectile Dysfunction

Efficacy and Safety of MED2005, a Topical Glyceryl Trinitrate Formulation, in the Treatment of Erectile Dysfunction: A Randomized Crossover Study

View publication

An open-label, parallel-group, repeat-dose study

An open-label, parallel-group, repeat-dose study to investigate the effects of end-stage renal disease and haemodialysis on the pharmacokinetics of ropinirole. Tompson et al. 13th International Congress of Parkinson’s Disease and Movement

View publication

Effect of oseltamivir treatment on anticoagulation

Effect of oseltamivir treatment on anticoagulation: a cross-over study in warfarinized patients. Davies B et al. Br J Clin Pharmacol 2010;70(6):834-843. Single centre drug interaction study in 20 patient volunteers on regular warfarin. The study

View publication

Benefits of a Single Versus Multicenter Approach in Early-Phase Patient Studies

Benefits of a Single Versus Multicenter Approach in Early-Phase Patient Studies; A Case Study of Multiple Sclerosis Patients. Berelowitz et al. The Monitor Page 21-25. October 2011

View publication

Pharmacodynamic Consequences of Administration of VLA-4 Antagonist CDP323 to Multiple Sclerosis Subjects

Pharmacodynamic Consequences of Administration of VLA-4 Antagonist CDP323 to Multiple Sclerosis Subjects: A Randomized, Double-Blind Phase 1/2 Study. Wolf et al. PLOS ONE Journal. March 2013 | Volume 8 | Issue 3 | e58438

View publication

Corporate Information

Copyright Licensing Agency Licence Certificate 2020-21

This is to certify that The Copyright Licensing Agency Limited (“CLA”) has granted a Licence...

View publication

MHRA Phase I Accreditation Certificate (August 2020)

MHRA Phase I Accreditation Certificate (August 2020)

View publication

MHRA Phase I Accreditation Certificate (April 2017)

MHRA Phase I Accreditation Certificate (April 2017)

View publication

MHRA Phase I Accreditation Certificate (March 2015)

MHRA Phase I Accreditation Certificate (March 2015)

View publication

MHRA Phase I Accreditation Certificate (March 2013)

MHRA Phase I Accreditation Certificate (March 2013)

View publication

Corporate Accounts 2018

Corporate Accounts 2018

View publication

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more